JAMA
Original Investigation
April 13, 2021
Eduardo López-Medina, MD, MSc; Pío López, MD; Isabel C . Hurtado , MD; Diana M Dávalos, MD, MPH, DrPH; Oscar Ramirez, MD, MPhil; Ernesto Martínez, MD; Jesus A. Díazgranados, MD; José M. Oñate, MD; Hector Chavarriaga, MD, MS; Sócrates Herrera, MD; Beatriz Parra, PhD; Gerardo Libreros, PhD; Roberto Jaramillo, MD; Ana C. Avendaño, MD; Dilian F. Toro, MD; Miyerlandi Torres, DrPH; Maria C. Lesmes, MD; Carlos A. Rios, MD; Isabella Caicedo, MD
free access
is active quiz
JAMA. 2021; 325(14):1426-1435. doi: 10.1001/jama.2021.3071
This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.